DuPont puts medical products businesses on the market
This article was originally published in Clinica
US chemicals group DuPont wants to exit the medical devices sector, following in the footsteps of Eli Lilly. DuPont has put its four medical products businesses up for sale to part-finance $8,800 million share purchase from Seagram in April. DuPont had indicated before that it would sell about $2,000 million worth of assets to this end. The sale does not include DuPont's half share in DuPont Merck Pharmaceutical.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.